Roche’s Q2 Results Reaffirm Our Bullish Stance

+29.53%
Upside
32.64
Market
42.28
Trefis
RHHBY: Roche logo
RHHBY
Roche

Roche (NASDAQ: RHHBY) reported its Q2 results on 21 July,2016. The company continued to show strong growth in its oncology division. Even the diagnostic division was not behind. Considering the strong growth, we continue to remain bullish on Roche shares.

Key Takeaways From Q2 Earnings

1) Oncology Continues To Show Strong Growth

Relevant Articles
  1. Is Roche Stock Undervalued At $33?
  2. What’s Driving Roche Stock?
  3. Company Of The Day: Roche Holdings
  4. What’s Happening With Roche (RHHBY) Stock?
  5. What’s Next For Roche Stock?
  6. Should You Buy, Sell, Or Hold Roche Stock At $42?

2) Diagnostics Division Saw Growth Boost

3) International Expansion Seems To Be The Major Reason

4) Overall We Continue To Maintain Bullish Stance

RHHBY-Q2

Sources:

[1] Roche Holding’s (RHHBY) CEO Severin Schwan on Q2 2016 Results – Earnings Call Transcript, Seeking Alpha, July 21,2016

[2] Roche Earnings Q2 Results, Roche, July 21,2016

Have more questions about Roche? See the links below.

Notes:

1) The purpose of these analyses is to help readers focus on a few important things. We hope such lean communication sparks thinking, and encourages readers to comment and ask questions on the comment section, or email content@trefis.com
2) Figures mentioned are approximate values to help our readers remember the key concepts more intuitively. For precise figures, please refer to our complete analysis for Roche

See More at Trefis | View Interactive Institutional Research (Powered by Trefis)

Get Trefis Technology